Subcutaneous Opdivo improves cancer care by offering faster, accessible therapy, reducing time toxicity and expanding patient ...
Post-operative nivolumab significantly improved disease-free survival in resected locally advanced head and neck cancer, ...
The addition of adjuvant nivolumab to standard-of-care radiotherapy and cisplatin improved survival for patients with locally ...
Dr. Balazs Halmos discusses the significance of the FDA approval of the subcutaneous injection formulation of Opdivo for ...
Matthew R. Zibelman, MD, discusses treatment options in muscle-invasive, perioperative, and metastatic bladder cancer.
BioWorld™ publish (NYSE:CLVT), a leading global provider of transformative intelligence, has released its highly anticipated ...
Medpage Today on MSN6d
A Win for AI in Cancer; 2025's Transformative Drugs; FDA Clarifies 'Underway' TrialsThe Head and Neck Radiation Oncology Group (GORTEC) announced significant improvement in disease-free survival for locally ...
Oncology nurses can educate patients on the benefits of subcutaneous administration, including reduced time in the infusion ...
BMS announced on Friday that Opdivo (nivolumab) had failed to show superiority to standard chemotherapy as a monotherapy in treatment naïve NSCLC patients, a result which was a huge shock ...
including Merck & Co. The US regulator cleared BMS' LAG-3 drug relatlimab as a fixed-dose combination with its PD-1 inhibitor Opdivo (nivolumab) – under the Opdualag brand name – in patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback